- Diagnostic Différentiel
Drug Information for OCUFLOX (ofloxacin ophthalmic solution) 0.3%sterile (Allergan, Inc.): WARNINGS
- INDICATIONS AND USAGE
- DOSAGE AND ADMINISTRATION
- HOW SUPPLIED
- Diseases/Conditions Related to OCUFLOX (ofloxacin ophthalmic solution) 0.3%sterile (Allergan, Inc.)
- Liens externes liés à OCUFLOX (ofloxacin ophthalmic solution) 0.3%sterile (Allergan, Inc.)
NOT FOR INJECTION.
OCUFLOX® solution should not be injected subconjunctivally, nor should it be introduced directly into the anterior chamber of the eye.
Serious and occasionally fatal hypersensitivity (anaphylactic) reactions, some following the first dose, have been reported in patients receiving systemic quinolones, including ofloxacin. Some reactions were accompanied by cardiovascular collapse, loss of consciousness, angioedema (including laryngeal, pharyngeal or facial edema), airway obstruction, dyspnea, urticaria, and itching. A rare occurrence of Stevens-Johnson syndrome, which progressed to toxic epidermal necrolysis, has been reported in a patient who was receiving topical ophthalmic ofloxacin. If an allergic reaction to ofloxacin occurs, discontinue the drug. Serious acute hypersensitivity reactions may require immediate emergency treatment. Oxygen and airway management, including intubation should be administered as clinically indicated.
- Drug Information Provided by National Library of Medicine (NLM).